Monument Therapeutics Logo Header


Our CEO Jennifer Barnett will be speaking at the Neuroimmunology Drug Development Summit, taking place next week in Boston, MA.

Don’t miss her in-person talk:
Using Digital Biomarkers to Apply a Stratified Approach to Neuroinflammation
When: April 19th, 9AM EST


  • Applying digital biomarkers, in combination with standard inflammatory markers, to aid identification of people at high risk for neuroinflammation
  • Using prophylactic small molecule approach for neuroinflammation to analyze neuroinflammatory outcomes in patients with post-operative cognitive decline in
  • Referencing the outcomes of the clinical trials conducted by Monument Tx to outline the above


Can’t attend the event but want to learn more our work applying digital biomarkers to aid identification of people at high risk for #neuroinflammation? Contact us directly:

For further information, contact:

Jenny Barnett, CEO